Insmed Inc. has announced that it will present four abstracts on treprostinil palmitil inhalation powder (TPIP) at the Pulmonary Vascular Research Institute (PVRI) 2026 Congress, scheduled to take place in Dublin from January 28 to February 1, 2026. The presentations will include the study design for the Phase 3 PALM-PAH trial, an encore presentation of previously disclosed topline data from the Phase 2b study in patients with pulmonary arterial hypertension (PAH), a new functional respiratory imaging analysis from the Phase 2b study, and preclinical data on pulmonary vasodilation in rat models. The results from the Phase 2b study have already been presented, while the additional data and study design details will be presented at the upcoming congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY72368) on January 28, 2026, and is solely responsible for the information contained therein.